Amgen, Inc.

  • There Is No Such Thing as a Crash-Proof Stock

    By Timothy Green - August 16, 2013 | Tickers: AMGN, AAPL, CVX, XOM

    Over on MarketWatch an article entitled "Three crash-proof blue-chip stocks" was published on Monday, in which the author put forth three big-name stocks that he believed could weather a pullback better than the rest. The three stocks put forth were Exxon Mobil (NYSE: XOM), Amgen (NASDAQ: AMGN), and, believe it or not, Apple (NASDAQ: AAPL).

    But there is no such thing as a crash-proof stock, and for a long-term investor more »

  • Biotech Stocks- A Dangerous Perscription

    By Justin Carley - August 7, 2013 | Tickers: AMGN, CELG, GILD

    Biotechnology shares have exploded in recent quarters thanks to M&A offers and rumors as well as favorable drug trial data. The market appears to be taking recent growth and extrapolating it well into the future, which is always a dangerous thing to do. Investors in biotechnology stocks may have forgotten the dangers of slower than expected earnings growth coupled with P/E multiple compression, especially those that have committed more »

  • Amgen: Onyx Pharmaceuticals Is Worth A Few Dollars More...

    By Amod Saul - August 7, 2013 | Tickers: AMGN, JNJ, ONXX

    It seems Amgen (NASDAQ: AMGN) has decided that Onyx Pharmaceuticals (NASDAQ: ONXX) is worth a few dollars more than the $120 per share it offered a few weeks ago. News agencies are filled with anonymously sourced reports that Amgen is planning to raise its bid to $130 per share.

    If accepted, the acquisition would give Amgen full rights to Onyx's Kyprolis (carfilzomib), a small molecule injectable proteasome inhibitor approved more »

  • A Closer Look at the Battle Over Cancer Treatments

    By Leo Sun - August 6, 2013 | Tickers: AMGN, INO, MRK, ONXX, PFE

    Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are struggling to avoid the upcoming patent cliff by acquiring companies with promising oncology treatments. In this article, I’ll take a look at several of the key companies to follow in this field, and what investors can expect from this fast more »

  • Great Pipelines, Unimpressive Fundamentals

    By Harriet Tramer - July 25, 2013 | Tickers: AMGN, GILD, MYL

    Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered untreatable. So, they should enjoy an expanding customer base; as our country ages increasingly more people will benefit from life saving medical advances.

    But does that necessarily mean companies, such as Amgen (NASDAQ: AMGN), Gilead Science (NASDAQ: GILD) and Mylan (NASDAQ: MYL), which are heavily involved in more »

  • Will This Biotech Bidding War Lead You to Larger Gains?

    By Sherrie Stone - July 24, 2013 | Tickers: AMGN, AZN, NVS, ONXX, PFE

    Onyx Pharmaceuticals (NASDAQ: ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout. Reportedly, four companies are prepping bids to acquire Onyx. What is a fair price for the company, and should you buy now?

    Why the Interest?

    If $120 a share significantly undervalues the company, according to Onyx, then what is a fair price? This question can only be answered when you more »

  • Is Big Biotech Still Growing?

    By Seth Robey - July 24, 2013 | Tickers: AMGN, BIIB, CELG, GILD, IBB

    The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotech ETF (NASDAQ: IBB) up >40% YTD.  The industry continues to climb with development-stage companies cranking out innovative pipelines.   As biotech's biggest company, Amgen (NASDAQ: AMGN) is beginning to look more like Big Pharma than its biotech growth peers.  It has high margins, a comparatively low valuation, and is the only biotech more »

  • Expanding Labels to Expand Margins

    By Seth Robey - July 18, 2013 | Tickers: ABBV, AMGN, CELG, JNJ, ONXX, PFE

    In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health. Is cash being applied efficiently to maximize sales while minimizing the cost of R&D? Perhaps the most powerful way to maximize revenue potential and minimize cost is through label expansion.

    Companies with nascent revenue streams must appropriately limit costs while fostering newfound more »

  • Merck's Late-Stage Breakdown

    By Brandy Betz - July 18, 2013 | Tickers: AMGN, MRK, SNY

    The Food and Drug Administration cancelled an advisory meeting planned for Merck’s (NYSE: MRK) post-surgery drug sugammadex. It’s another blow to Merck as investors pay close attention to the beleaguered R&D department now turned over to Roger Perlmutter.

    Merck highlighted its top five late-stage projects during the full-year 2011 conference call last February: sugammadex, insomnia treatment suvorexant, HPV vaccine V503, osteoporosis drug odanacatib, and cholesterol drug Tredaptive more »

  • How Valuable Is a Cheaper Treatment for Arthritis?

    By Kanak Kanti - July 15, 2013 | Tickers: ABBV, AMGN, HSP, JNJ

    Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide – might not be able to afford. On the other hand, cheaper generic drugs are not as effective. Now, Hospira (NYSE: HSP) is developing Inflectra, a biosimilar for Remicade, that will be safer and more effective than generic options, but at a fraction of the more »

  • Do Generic Drugs Drastically Alter Market Dynamics?

    By Kanak Kanti - July 9, 2013 | Tickers: ABBV, ACT, AMGN

    Pharma companies have been paying off generic drug makers so that cheap generic drugs do not enter the market. In a settlement case involving AbbVie (NYSE: ABBV), the U.S. Supreme Court dealt a blow to this practice, allowing the FTC to take action against these deals. The judgment is seen as a “significant victory for the consumers and free trade.” However, the market remains relatively unaffected.

    The case

    The more »

  • Who Is the Best Suitor for Onyx?

    By Vikas Shukla - July 8, 2013 | Tickers: AMGN, BAYRY.PK, ONXX

    Cancer-drug maker Onyx Pharmaceuticals (NASDAQ: ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen (NASDAQ: AMGN). Onyx also said that it is looking for potential suitors. The move has triggered speculations of a bidding war, sending the stock up 51.27% on Monday to $131.33.

    Amgen had offered to pay $120 per share in cash, a 38.2% premium to Onyx’s closing price of $86 more »

  • Amgen Stirs the Pot in the Cancer-Related Sector

    By Phillip Woolgar - July 6, 2013 | Tickers: AMGN, ONXX, PCYC

    Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to take any competitive advantage. The company that does manage to make the breakthrough that millions are waiting for will not only change the world, but also make a lot of shareholders very rich. 

    Amgen (NASDAQ: AMGN) in its more »

  • Watch Out for These 3 Biotech Companies

    By Madhukar Dubey - July 4, 2013 | Tickers: AMGN, BIIB, CELG

    The growth of the biotechnology industry is greatly influenced by research and development expenditure.

    This year, the North American players in the biotechnology industry are expected to spend $15 billion. This spending will be in the form of mergers and acquisitions as well as research and development. The North American market is an oligopolistic market where the majority of the revenue is made by a few dominating companies. With such more »

  • Is This Biopharmaceutical Stock Still a Buy?

    By Anh HOANG - July 4, 2013 | Tickers: AMGN, CELG, ONXX

    Onyx Pharmaceuticals (NASDAQ: ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share. The share price jump was due to the news that the company had received a $120 a share offer from Amgen (NASDAQ: AMGN) but rejected it as Onyx considered the offering price “significantly undervalued” the company. Let’s take a closer more »

  • Is This A Good Acquisition For All?

    By Brian Nichols - July 3, 2013 | Tickers: AMGN, GILD, ONXX

    For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals (NASDAQ: ONXX). After rejecting Amgen’s (NASDAQ: AMGN) $120 a share offer, some analysts are predicting the bidding war could reach $160. While many have come to the defense of Amgen, saying that $160 is too much, I think we should look back on recent history as proof that this more »

  • Avoid This Biotech Investment, For Now

    By Mohsin Saeed - July 3, 2013 | Tickers: AMGN, BAYRY.PK, ONXX

    Mergers and acquisitions have always been a big part of the biotechnology industry, and the patent cliff has further increased M&A activity. We are only mid-way into 2013, but the biotech industry has already seen M&A of over $93.6 billion, as the generic threat and empty pipelines are forcing big-pharmaceutical players to adopt aggressive M&A strategies.

    Onyx Pharmaceuticals (NASDAQ: ONXX) has said that it has rejected more »

  • Onyx Bidding Wars: Who Would Be the Best Suitor?

    By usman iftikhar - July 2, 2013 | Tickers: AMGN, CELG, GILD, ONXX

    A lot of activity is happening in the biotech industry which would change the dynamics of the large cancer related drug makers.

    Recently, Amgen (NASDAQ: AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx (NASDAQ: ONXX). Amgen offered $120 per share or roughly $10 billion. Onyx rejected the offer right away and is looking for other buyers now. With a successful cancer drug in the market and more »

  • Should You Invest in These Cancer Treatment Biotechs?

    By Leo Sun - July 2, 2013 | Tickers: AMGN, IMGN, IMMU, ONXX, SGEN

    Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country. 1.7 million new cases of cancer are expected to be diagnosed in 2013, and nearly 1,600 people die from the disease daily. This makes the race to cure cancer one of the most important goals of the biotech industry, and recent developments indicate that more »

  • Amgen vs. Big Pharma: It's Amgen for the Long Term

    By Nancy Tengler - July 1, 2013 | Tickers: AMGN, BMY, MRK

    Over the last three decades I have seen my share of bull and bear markets. And though no market cycle is exactly the same, there are eternal investing principles shareholders can depend upon like my Intelligent Investing Rule #1: Buy Great Companies for the Long-Term.  

    Buying big pharma and biotech stocks requires a long-term focus

    Large-cap pharmaceutical and biotechnology companies have performed relatively well over the last year but still more »

  • Page 1 of 5